{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T16:11:38Z","timestamp":1781712698085,"version":"3.54.5"},"reference-count":13,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005565","name":"Johnson & Johnson Innovative Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005565","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005205","name":"Johnson & Johnson Innovative Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.jns.2025.125700","type":"journal-article","created":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T16:09:33Z","timestamp":1766246973000},"page":"125700","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Serological testing patterns among individuals newly diagnosed with myasthenia gravis"],"prefix":"10.1016","volume":"480","author":[{"given":"A.","family":"Pesa Jacqueline","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Liberman Joshua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Darer Jonathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Xiaoyun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Jackson Louis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergenyenko","family":"Artem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Campbell","family":"Nolan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Nowak Richard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2025.125700_bb0005","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2024.1339167","article-title":"Epidemiology of myasthenia gravis in the United States","volume":"15","author":"Ye","year":"2024","journal-title":"Front. Neurol."},{"issue":"9","key":"10.1016\/j.jns.2025.125700_bb0010","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1002\/acn3.52122","article-title":"The impact of diagnosis delay on European patients with generalised myasthenia gravis","volume":"11","author":"Cort\u00e9s-Vicente","year":"2024","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.jns.2025.125700_bb0015","doi-asserted-by":"crossref","DOI":"10.1177\/17562864231213240","article-title":"Guideline for the management of myasthenic syndromes","volume":"16","author":"Wiendl","year":"2023","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"11","key":"10.1016\/j.jns.2025.125700_bb0020","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3389\/fimmu.2020.00212","article-title":"Autoantibody specificities in myasthenia gravis; implications for improved diagnostics and therapeutics","volume":"14","author":"Lazaridis","year":"2020","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.jns.2025.125700_bb0025","doi-asserted-by":"crossref","first-page":"290","DOI":"10.21037\/atm-19-363","article-title":"Serological diagnosis of myasthenia gravis and its clinical significance","volume":"11","author":"Li","year":"2023","journal-title":"Ann. Transl. Med."},{"issue":"2","key":"10.1016\/j.jns.2025.125700_bb0030","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.nmd.2023.01.002","article-title":"Autoantibody detection by a live cell-based assay in conventionally antibody-tested triple seronegative myasthenia gravis","volume":"33","author":"Hoffmann","year":"2023","journal-title":"Neuromuscul. Disord."},{"issue":"6","key":"10.1016\/j.jns.2025.125700_bb0035","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1007\/s00415-021-10891-1","article-title":"Burden of disease in myasthenia gravis: taking the patient\u2019s perspective","volume":"269","author":"Lehnerer","year":"2022","journal-title":"J. Neurol."},{"key":"10.1016\/j.jns.2025.125700_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2024.123047","article-title":"Acetylcholinesterase inhibitors are ineffective in MuSK-antibody positive myasthenia gravis: results of a study on 202 patients","volume":"461","author":"Ricciardi","year":"2024","journal-title":"J. Neurol. Sci."},{"issue":"4","key":"10.1016\/j.jns.2025.125700_bb0045","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1007\/s40120-022-00383-3","article-title":"Physician-reported perspectives on myasthenia gravis in the United States: a real-world survey","volume":"11","author":"Mahic","year":"2022","journal-title":"Neurol. Ther."},{"issue":"1","key":"10.1016\/j.jns.2025.125700_bb0050","doi-asserted-by":"crossref","first-page":"7219","DOI":"10.1038\/s41598-025-90937-w","article-title":"Efficacy and safety of rituximab in anti-MuSK myasthenia gravis: a systematic review and meta-analysis","volume":"15","author":"Chayanopparat","year":"2025","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.jns.2025.125700_bb0055","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1111\/ene.15238","article-title":"The association between anti-acetylcholine receptor antibody level and clinical improvement in myasthenia gravis","volume":"29","author":"Marcuse","year":"2022","journal-title":"Eur. J. Neurol."},{"issue":"9","key":"10.1016\/j.jns.2025.125700_bb0060","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.3390\/brainsci13091286","article-title":"Diagnosis and management of seronegative myasthenia gravis: lights and shadows","volume":"13","author":"Vinciguerra","year":"2023","journal-title":"Brain Sci."},{"key":"10.1016\/j.jns.2025.125700_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2022.577850","article-title":"The clinical need for clustered AChR cell-based assay testing of seronegative MG","volume":"367","author":"Masi","year":"2022","journal-title":"J. Neuroimmunol."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X25023202?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X25023202?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T22:45:14Z","timestamp":1768949114000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X25023202"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":13,"alternative-id":["S0022510X25023202"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2025.125700","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serological testing patterns among individuals newly diagnosed with myasthenia gravis","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2025.125700","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"125700"}}